Evidence map›Paper›PMID 34568801›Full record

ArticleJHEP reports : innovation in hepatology2021

Autophagy-mediated reduction of miR-345 contributes to hepatic cystogenesis in polycystic liver disease.

Tatyana Masyuk, Anatoliy Masyuk, Christy Trussoni, Brynn Howard, Jingyi Ding, Bing Huang, Nicholas LaRusso

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JHEP reports : innovation in hepatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Dysregulation of the Scribble/YAP/β-catenin axis sustains the fibroinflammatory response in a PKHD1FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2022
    Article
  4. Role of Immune Cells in Biliary Repair.Frontiers in immunology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Tatyana MasyukDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Anatoliy MasyukDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Christy TrussoniDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Brynn HowardDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Jingyi DingDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Bing HuangDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Nicholas LaRussoDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Mayo Clinic in Arizona · US

Funding

PILOT AND FEASIBILTY PROGRAMP30DK084567 · NIDDK · MAYO CLINIC ROCHESTER · PI Nicholas F. LaRusso · 2009 to 2026
$22.2M
The Pathobiology of Hepatic EpitheliaR01DK024031 · NIDDK · MAYO CLINIC ROCHESTER · PI LARUSSO, NICHOLAS F. · 1986 to 2023
$10.4M
NIDDK NIH HHS P30 DK084567NIDDK NIH HHS R01 DK024031
6 · The paper itself

Abstract

BACKGROUND &

aimsPolycystic liver disease (PLD) is characterised by increased autophagy and reduced miRNA levels in cholangiocytes. Given that autophagy has been implicated in miRNA regulation, we tested the hypothesis that increased autophagy accounts for miRNA reduction in PLD cholangiocytes (PLDCs) and accelerated hepatic cystogenesis.

methodsWe assessed miRNA levels in cultured normal human cholangiocytes (NHCs), PLDCs, and isolated PLDC autophagosomes by miRNA-sequencing (miRNA-seq), and miRNA targets by mRNA-seq. Levels of miR-345 and miR-345-targeted proteins in livers of animals and humans with PLD, in NHCs and PLDCs, and in PLDCs transfected with pre-miR-345 were assessed by

resultsIn total, 81% of miRNAs were decreased in PLDCs, with levels of 10 miRNAs reduced by more than 10 times; miR-345 was the most-reduced miRNA.

conclusionAutophagy-mediated reduction of miR-345 in PLDCs ( LAY SUMMARY: Polycystic liver disease (PLD) is an incurable genetic disorder characterised by the progressive growth of hepatic cysts. We found that hepatic cystogenesis is increased when the levels of miR-345 in PLD cholangiocytes (PLDCs) are reduced by autophagy. Restoration of miR-345 in PLDCs via inhibition of autophagy decreases hepatic cystogenesis and thus, is beneficial for PLD.

Indexed as

ADPKD, autosomal dominant polycystic kidney diseaseADPLD, autosomal dominant polycystic liver diseaseAGO2, Argonaute 2ALG8, alpha-1,3-glucosyltransferaseALG9, alpha-1,2-mannosyltransferaseARPKD, autosomal recessive polycystic kidney diseaseCDC25A, cell division cycle 25ACDK6, cyclin-dependent kinase 6Cell cycle-related proteinsCholangiocyte proliferationCholangiocytesDNAJB11, DnaJ heat shock protein family (Hsp40) member B11DZIP1L, DAZ interacting zinc finger protein 1 likeFDR, false discovery rateGANAB, glucosidase II alpha subunitGenetic liver diseasesGO, Gene OntologyHCQ, hydroxychloroquineISH, in situ hybridisationKEGG, Kyoto Encyclopedia of Genes and GenomesLRP5, low-density lipoprotein receptor-related protein 5miRISC, RNA-induced silencing complexmiRNA-seq, miRNA-sequencingmTOR, mammalian target of rapamycinNHC, normal human cholangiocyteNRC, normal rat cholangiocytePCKC, polycystic kidney rat cholangiocytePCK, polycystic kidneyPCNA, proliferating cell nuclear antigenPKD1/2, polycystic kidney disease 1/2PKHD1, polycystic kidney and hepatic disease 1PLDC, polycystic liver disease cholangiocytePLD, polycystic liver diseasePLD treatmentPRKCSH, protein kinase C substrate 80K-HRPM, reads per millionSEC61B, SEC61 translocon subunit betaSEC63, SEC63 homolog, protein translocation regulatorsnRNA, small nuclear RNAWT, wild type

Identifiers

PMID34568801
PMCPMC8449272
OpenAlexW3191881183

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.